Psychedelic Brief

Deals

DateTargetAcquirer or investorTypeHeadline total
16 July 2026AtaiBeckley Inc.Eli Lilly and Companyacquisition$3.8bn
1 October 2025Gilgamesh Pharmaceuticals, Inc.AbbVie Inc.acquisition$1.2bn
2 June 2025Beckley Psytech Limitedatai Life Sciences N.V. (renamed Atai Beckley N.V. on completion)acquisitionNot disclosed